Plus Therapeutics (NASDAQ:PSTV) Now Covered by Lake Street Capital

Equities research analysts at Lake Street Capital started coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note issued on Tuesday. The firm set a “buy” rating and a $2.00 price target on the stock.

PSTV has been the subject of a number of other reports. Zacks Research downgraded Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. D. Boral Capital cut their price target on shares of Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Ascendiant Capital Markets reduced their price target on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $1.00 target price (down from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.80.

Plus Therapeutics Trading Up 6.1%

Shares of NASDAQ:PSTV opened at $0.24 on Tuesday. The stock has a market cap of $33.61 million, a PE ratio of -0.13 and a beta of 0.89. The stock’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.54. Plus Therapeutics has a 1-year low of $0.16 and a 1-year high of $2.31.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Susquehanna International Group LLP bought a new stake in shares of Plus Therapeutics during the 3rd quarter valued at about $46,000. Scientech Research LLC purchased a new stake in Plus Therapeutics in the third quarter valued at approximately $100,000. Altium Capital Management LLC bought a new stake in Plus Therapeutics during the third quarter valued at approximately $628,000. Finally, Jane Street Group LLC bought a new stake in Plus Therapeutics during the second quarter valued at approximately $41,000. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.